10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Prrx1 Antibody - C-terminal region

Rabbit Polyclonal Antibody
Catalog # AI11577

Product Information

Application	WB
Primary Accession	P63014
Other Accession	NM_153821, NP_722543
Reactivity	Human, Mouse, Rat, Rabbit, Zebrafish, Dog, Bovine
Predicted	Human, Mouse, Rat, Pig, Dog, Bovine
Host	Rabbit
Clonality	Polyclonal
Calculated MW	27269

Additional Information


Gene ID	266813
Alias Symbol	Pmx1, Prx-1
Other Names	Paired mesoderm homeobox protein 1, Paired-related homeobox protein 1, PRX-1, rHox, Prrx1
Format	Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.
Reconstitution & Storage	Add 50 ul of distilled water. Final anti-Prrx1 antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles.
Precautions	Prrx1 Antibody - C-terminal region is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

Name	Prrx1
Function	Master transcription factor of stromal fibroblasts for myofibroblastic lineage progression. Orchestrates the functional drift of fibroblasts into myofibroblastic phenotype via TGF-beta signaling by remodeling a super-enhancer landscape. Through this function, plays an essential role in wound healing process. Acts as a transcriptional regulator of muscle creatine kinase (MCK) and so has a role in the establishment of diverse mesodermal muscle types. The protein binds to an A/T-rich element in the muscle creatine enhancer. May play a role in homeostasis and regeneration of bone, white adipose tissue and derm.

Cellular Location	Nucleus {ECO:0000250|UniProtKB:P63013, ECO:0000255|PROSITE-ProRule:PRU00108, ECO:0000255|PROSITE-ProRule:PRU00138}

Images



Host: Rabbit
Target Name: Prrx1
Sample Tissue: Rat Pancreas lysates
Antibody Dilution: 1.0µg/ml

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.